EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease

Sudesh Prajapathi, Kunal Mahajan iD, Aditi Mohta iD, Akshyaya Pradhan iD

Journal of the American Heart Association · 05.05.2026 · 15 (9)

DOI: 10.1161/jaha.125.047676 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 05.05.2026. Verfasst von Sudesh Prajapathi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology All India Institute of Medical Sciences Bhopal Madhya Pradesh India. Hauptthemen laut MEDLINE: Cholesterol Ester Transfer Proteins, Anticholesteremic Agents, Atherosclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic cardiovascular diseases are a leading global cause of death, driven significantly by elevated low‐density lipoprotein cholesterol levels. Despite the emergence of effective lipid‐lowering therapies such as statins and other agents, a significant proportion of high‐risk patients fail to reach the recommended low‐density lipoprotein cholesterol targets. This highlights a critical unmet need for additional lipid‐lowering therapies that are not only efficacious and orally administered, but also demonstrate durable safety and cardiovascular benefits. CETP (cholesteryl ester transfer protein) inhibition alters lipid metabolism by preventing the transfer of cholesteryl esters from high‐density lipoprotein to apolipoprotein B–containing lipoproteins, thereby reducing atherogenic cholesterol burden. CETP inhibitors have had a challenging development history due to off‐target effects observed in early compounds like torcetrapib. However, obicetrapib is a highly selective and hydrophilic CETP inhibitor that heralds a promising new generation of drugs with robust lipid‐lowering capabilities and a favorable safety profile. This review presents a comprehensive overview of obicetrapib's mechanism of action, its pharmacokinetic and pharmacodynamic profiles, and a detailed critical assessment of its clinical development through various pivotal trials including TULIP (TA‐8995: Its Use in Patients With Mild Dyslipidemia), ROSE (Trial Evaluating Obicetrapib in Combination With Ezetimibe), ROSE2 (Phase 2b ROSE Trial Evaluating Obicetrapib in Combination With Ezetimibe), BROADWAY (Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid‐Modifying Therapies), BROOKLYN (Obicetrapib on Top of Maximum Tolerated Lipid‐Modifying Therapies, TANDEM (Study of Obicetrapib and Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid‐Modifying Therapies), and the ongoing PREVAIL (Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease) cardiovascular outcomes trial. We compare the efficacy, safety, and tolerability of obicetrapib against prevailing treatment options, positioning it as a potential oral adjunct to maximally tolerated lipid‐lowering regimens in the current lipid management landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholesterol Ester Transfer ProteinsAnticholesteremic AgentsAtherosclerosisHumansAnimalsTreatment Outcome

Stichwörter der Autor:innen

LDL‐C loweringatherosclerotic cardiovascular diseasecholesteryl ester transfer protein inhibitorslipid‐lowering therapyobicetrapib

Substanzen

Cholesterol Ester Transfer ProteinsAnticholesteremic AgentsCETP protein, human

Autor:innen und Institutionen

  • Department of Cardiology All India Institute of Medical Sciences Bhopal Madhya Pradesh India.
  • Himachal Heart Institute Mandi Himachal Pradesh India.
  • Department of Community Medicine People's College of Medical Sciences & Research Centre, People's University Bhopal Madhya Pradesh India.
  • Department of Cardiology King George's Medical University Lucknow Uttar Pradesh India.

ORCID-Profile: Kunal Mahajan, Aditi Mohta, Akshyaya Pradhan

Zitieren

APA

Prajapathi, S., Mahajan, K., Mohta, A., & Pradhan, A. (2026). From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association, 15(9). https://doi.org/10.1161/jaha.125.047676

Vancouver

Prajapathi S, Mahajan K, Mohta A, Pradhan A. From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease. Journal of the American Heart Association. 2026;15(9). doi:10.1161/jaha.125.047676

BibTeX
@article{Prajapathi2026,
  author = {Prajapathi, Sudesh and Mahajan, Kunal and Mohta, Aditi and Pradhan, Akshyaya},
  title = {From Failure to Promise: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition in Atherosclerotic Cardiovascular Disease},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {9},
  doi = {10.1161/jaha.125.047676}
}
Kostenlos starten →